Swiss National Bank
CGON icon

Swiss National Bank’s CG Oncology CGON Stock Holding History

Swiss National Bank’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.23M Buy
101,700
+17,300
+20% +$1.13M ﹤0.01% 1222
2026
Q1 		$5.71M Hold
84,400
– – ﹤0.01% 1288
2025
Q4 		$3.5M Buy
84,400
+3,100
+4% +$128K ﹤0.01% 1569
2025
Q3 		$3.27M Buy
81,300
+1,200
+1% +$34.9K ﹤0.01% 1583
2025
Q2 		$2.08M Sell
80,100
-1,000
-1% -$24.1K ﹤0.01% 1794
2025
Q1 		$1.99M Buy
81,100
+1,500
+2% +$42.2K ﹤0.01% 1773
2024
Q4 		$2.28M Buy
79,600
+47,000
+144% +$1.61M ﹤0.01% 1771
2024
Q3 		$1.23M Sell
32,600
-6,800
-17% -$238K ﹤0.01% 2123
2024
Q2 		$1.24M Buy
+39,400
New +$1.37M ﹤0.01% 2063

Other funds holding CGON

RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Swiss National Bank's CGON Position: Q2 2026 in Review

Swiss National Bank increased its CG Oncology (CGON) stake by 20% in Q2 2026, buying an estimated $1.13M and bringing the position to 101,700 shares worth $7.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

Swiss National Bank first reported a position in CGON in Q2 2024 and has held it in 9 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Swiss National Bank held 101,700 shares of CG Oncology worth $7.23M as of Q2 2026.
  • Swiss National Bank bought 17,300 CG Oncology shares in Q2 2026, an estimated $1.13M.
  • CG Oncology made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1222 holding.
  • Swiss National Bank first reported a position in CG Oncology in Q2 2024 and has held it in 9 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.